Advancement from Small Peptide Pharmaceuticals to Orally Active Piperazine-2,5-dion-Based Cyclopeptides
Vladislav Deigin, Natalia Linkova, Olga Volpina · 2023 · International Journal of Molecular Sciences 24(17):13534
What does this source report?
Development-group review connecting small peptides with cyclic peptidomimetics, including AWE18. AWE18 and CP-88 are separate candidates. Review descriptions of oral activity are not independent clinical trials.
- Population and setting
- Source-specific experimental population
- Evidence type
- Review
- Preparation
- Defined synthetic peptide / analogue
- Source language
- English
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Independent replication and full risk-of-bias appraisal remain unresolved.
- No personalized treatment or safety conclusion follows from this record.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
Review full text retrieved via Europe PMC. Primary compound-specific studies require separate appraisal.
Recorded source-check date: 2026-10-02. This date does not imply a completed systematic review.
Cite and trace this record
Original source: Vladislav Deigin, Natalia Linkova, Olga Volpina. Advancement from Small Peptide Pharmaceuticals to Orally Active Piperazine-2,5-dion-Based Cyclopeptides International Journal of Molecular Sciences 24(17):13534 2023.
Molekul research summary: https://molekul.io/research/gaps-platform-review-2023. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
Stemokin / Neogen
Synthetic Ile–Glu–Trp tripeptide (IEW), studied in hematopoietic experiments and Russian clinical immune research. It is distinct from whole tissue extracts.
Thymodepressin
Synthetic Glu–Trp-derived dipeptide in the suppressive branch of this research program. Stereochemistry and peptide-bond position matter.
AWE18
Experimental cyclic Ala/Glu/Trp peptidomimetic discussed in the development literature. Its evidence must remain separate from CP-88.
Thymogen
EW is discussed in the thymus-derived research program. Thymalin extract outcomes cannot be assigned to this defined peptide.